Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 2, 2010, Pages 430-438

  Luo, Pengcheng ^a,b   Chang, Hsin Hsin ^a   Zhou, Yiqiang ^a   Zhang, Shali ^a   Hwang, Sung Hee ^c   Morisseau, Christophe ^c   Wang, Cong Yi ^a   Inscho, Edward W ^a   Hammock, Bruce D ^c   Wang, Mong Heng ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZOXIDE; ENZYME INHIBITOR; EPOXIDE HYDROLASE; GLUCAGON; GLUCOSE; INSULIN; SODIUM CHLORIDE; SOLUBLE EPOXIDE HYDROLASE; TRANS 4 [ 4 ( 3 ADAMANTAN 1 YLUREIDO)CYCLOHEXYLOXY]BENZOIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME REGULATION; EPHX2 GENE; GENE TARGETING; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; KNOCKOUT GENE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ANIMALS; APOPTOSIS; BENZOIC ACIDS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIAZOXIDE; EPOXIDE HYDROLASES; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN; INTRACELLULAR SPACE; ISLETS OF LANGERHANS; MICE; MICE, KNOCKOUT; STREPTOZOCIN; UREA;

EID: 77954902049     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.167544     Document Type: Article

References (35)

1. Breyer MD, Böttinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K, and AMDCC (2005) Mouse models of diabetic nephropathy. J Am Soc Nephrol 16:27-45.
2. Chan CB, Saleh MC, Koshkin V, and Wheeler MB (2004) Uncoupling protein 2 and islet function. Diabetes 53:S136-S142.
3. Chiamvimonvat N, Ho CM, Tsai HJ, and Hammock BD (2007) The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 50:225-237. (Pubitemid 47428969)
4. Dai T, Patel-Chamberlin M, Natarajan R, Todorov I, Ma J, LaPage J, Phillips L, Nast CC, Becerra D, Chuang P, et al. (2009) Heat shock protein 27 overexpression mitigates cytokine-induced islet apoptosis and streptozotocin-induced diabetes. Endocrinology 150:3031-3039.
5. Danial NN, Walensky LD, Zhang CY, Choi CS, Fisher JK, Molina AJ, Datta SR, Pitter KL, Bird GH, Wikstrom JD, et al. (2008) Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med 14:144-153.
6. Deng Y, Theken KN, and Lee CR (2010) Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J Mol Cell Cardiol 48:331-341.
7. Donath MY, Størling J, Berchtold LA, Billestrup N, and Mandrup-Poulsen T (2008) Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 29:334-350.
8. Falck JR, Manna S, Moltz J, Chacos N, and Capdevila J (1983) Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets. Biochem Biophys Res Commun 114:743-749.
9. Fukuda K, Tesch GH, Yap FY, Forbes JM, Flavell RA, Davis RJ, and Nikolic-Paterson DJ (2008) MKK3 signalling plays an essential role in leukocyte-mediated pancreatic injury in the multiple low-dose streptozotocin model. Lab Invest 88:398-407.
10. + channels in mouse B cells. J Clin Invest 89:1288-1295.
11. Gromada J, Duttaroy A, and Rorsman P (2009) The insulin receptor talks to glucagon? Cell Metab 9:303-305.
12. Gupta RK, Vatamaniuk MZ, Lee CS, Flaschen RC, Fulmer JT, Matschinsky FM, Duncan SA, and Kaestner KH (2005) The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion. J Clin Invest 115:1006-1015.
13. Henquin JC (2000) Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49:1751-1760.
14. Henquin JC (2004) Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes 53:S48-S58.
15. Henquin JC (2009) Regulation of insulin secretion: a matter of phase control and amplitude modulation. Diabetologia 52:739-751.
16. Imig JD (2005) Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289:F496-F503.
17. Imig JD (2006) Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev 24:169-188. (Pubitemid 46696923)
18. Imig JD, Zhao X, Capdevila JH, Morisseau C, and Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39:690-694.
19. Inscho EW, LeBlanc EA, Pham BT, White SM, and Imig JD (1999) Purinoceptor-mediated calcium signaling in preglomerular smooth muscle cells. Hypertension 33:195-200.
20. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
21. Kahn SE, Hull RL, and Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846.
22. Krauss S, Zhang CY, Scorrano L, Dalgaard LT, St-Pierre J, Grey ST, and Lowell BB (2003) Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest 112:1831-1842.
23. Liu JY, Tsai HJ, Hwang SH, Jones PD, Morisseau C, and Hammock BD (2009) Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation. Br J Pharmacol 156:284-296.
24. Loch D, Hoey A, Morisseau C, Hammock BO, and Brown L (2007) Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 47:87-98.
25. Mazzone T (2009) Hyperglycaemia and coronary heart disease: the meta picture. Lancet 373:1737-1738.
26. Müller A, Schott-Ohly P, Dohle C, and Gleichmann H (2002) Differential regulation of Th1-type and Th2-type cytokine profiles in pancreatic islets of C57BL/6 and BALB/c mice by multiple low doses of streptozotocin. Immunobiology 205:35-50. (Pubitemid 34285406)
27. Oshima H, Taketo MM, and Oshima M (2006) Destruction of pancreatic beta-cells by transgenic induction of prostaglandin E2 in the islets. J Biol Chem 281:29330-29336.
28. Roman RJ (2002) P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131-185.
29. Seubert JM, Sinal CJ, Graves J, DeGraff LM, Bradbury JA, Lee CR, Goralski K, Carey MA, Luria A, Newman JW, et al. (2006) Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99:442-450.
30. Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, Tsai HJ, Hammock BD, and Imig JD (2009) Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol 174:2086-2095.
31. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, and Gonzalez FJ (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275:40504-40510.
32. Uysal KT, Wiesbrock SM, Marino MW, and Hotamisligil GS (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610-614.
33. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, et al. (2001) Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413:131-138. (Pubitemid 32867868)
34. Zeldin DC, Foley J, Boyle JE, Moomaw CR, Tomer KB, Parker C, Steenbergen C, and Wu S (1997) Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 138:1338-1346.
35. Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, et al. (2001) Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 105:745-755.